COMP <GO>
MRKR vs NEUP // FREE CASH FLOW YIELD
Marker Therapeutics Inc. (NASDAQ) VS. Neuphoria Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: MRKR 2
— NEUP 2
■ METRIC PARITY
LAST: $1.01 (+1.00%) • MKT CAP: $16.8M
fcf-yield
—
LAST: $3.06 (-8.93%) • MKT CAP: $16.6M
fcf-yield
0.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRKR VS. NEUP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MRKR | NEUP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -11.80% | -23.20 | NEUP | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | — | 0.47% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -7.20% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -2.40% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 5/9 | -3.00 | NEUP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.7 | 25.4 | +19.30 | MRKR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.8M | $16.6M | $281.2K | MRKR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MRKR REV | NEUP REV | MRKR GROSS % | NEUP GROSS % | MRKR FCF | NEUP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $15.6M | — | — | -$12.0M | $77.2K |
| FY 2024 | $0 | $0 | — | — | -$10.9M | -$14.7M |
| FY 2023 | $0 | $0 | — | — | -$16.4M | -$14.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRKR // BETA —
NEUP // BETA —